IRD Opus Genetics, Inc.
Company Analysis
Latest News
🔴 Opus Genetics is trading 5.4% down today amid broader biotech sector rotation and profit-taking
Opus Genetics is trading 5.4% down today at $3.60 amid broader biotech sector rotation and profit-taking. • The decline extends a multi-day slide from above...
Opus Genetics Got the FDA's Blessing for a Tiny Trial — But Can an Eight-Patient Study Justify a $10 Price Target?
Shares of Opus Genetics (IRD) are consolidating around $4.28, up 5.7%, as traders digest the company's July 6 announcement that the FDA has signed off on the...
🟢 IRD is trading 6% up today on Phase 3 FDA alignment and bullish analyst commentary
IRD is trading about 6% up in pre-market near $4.28, rebounding from a recent pullback as investors react to Phase 3 FDA alignment for OPGx-LCA5 and bullish...
🔴 IRD is trading 5.4% down today following FDA alignment and analyst-driven surge
IRD is trading at $3.83 (5.4% down) in pre-market, giving back a portion of yesterday’s significant gains as the stock enters a consolidation phase. • The...
🟢 IRD Rises on FDA Alignment for Phase 3 Trial & Analyst Optimism
Opus Genetics (IRD) is trading at $4.29 (+5.41%) in pre-market sessions. This upward movement follows significant company developments including: • FDA...
🔴 Opus Genetics, Inc. is trading 8.85% down in pre-market
IRD is trading at $3.71, down 8.85% in pre-market.